United States securities and exchange commission logo





                              July 31, 2020

       Paul Kim
       Chief Financial Officer
       Fulgent Genetics, Inc.
       4978 Santa Anita Avenue, Suite 205
       Temple City, California 91780

                                                        Re: Fulgent Genetics,
Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed July 21, 2020
                                                            File No. 333-239964

       Dear Mr. Kim:

              We have limited our review of your registration statement to
those issues we have
       addressed in our comment.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comment applies to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to this comment, we may have additional comments.

       Registration Statement on Form S-3 filed July 21, 2020

       General

   1.                                                   We note that your forum
selection provision identifies the Court of Chancery in the State
                                                        of Delaware as the sole
and exclusive forum for certain litigation including any
                                                           derivative action
and excludes    actions in which a federal court has assumed exclusive
                                                        jurisdiction of a
proceeding.    Please disclose whether this provision applies to actions
                                                        arising under the
Securities Act or Exchange Act. In that regard, we note that Section 27
                                                        of the Exchange Act
creates exclusive federal jurisdiction over all suits brought to enforce
                                                        any duty or liability
created by the Exchange Act or the rules and regulations thereunder,
                                                        and Section 22 of the
Securities Act creates concurrent jurisdiction for federal and state
                                                        courts over all suits
brought to enforce any duty or liability created by the Securities Act
                                                        or the rules and
regulations thereunder. If the provision applies to Securities Act claims,
                                                        please also revise your
prospectus to state that there is uncertainty as to whether a court
 Paul Kim
Fulgent Genetics, Inc.
July 31, 2020
Page 2
       would enforce such provision and that investors cannot waive compliance
with the federal
       securities laws and the rules and regulations thereunder. If this
provision does not apply to
       actions arising under the Securities Act or Exchange Act, please also
tell us how you will
       inform investors in future filings that the provision does not apply to
any actions arising
       under the Securities Act or Exchange Act. In your revised disclosure,
please also explain
       the exclusion of    actions in which a federal court has assumed
exclusive jurisdiction to a
       proceeding    as it is unclear. To the extent that you intend for
actions in which a federal
       court has assumed exclusive jurisdiction    to mean that a court needs
to take action to
       assume jurisdiction to a proceeding under the Exchange Act, please note
that Section 27
       of the Exchange Act creates exclusive federal jurisdiction over all
suits brought to enforce
       any duty or liability created by the Exchange Act, regardless of whether
a court takes a
       specific action. If not, then your provision may incorrectly suggest
that federal courts have
       exclusive jurisdiction over Securities Act claims.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Jeffrey Gabor at 202-551-2544 or Mary Beth Breslin at
202-551-3625
with any questions.



                                                             Sincerely,
FirstName LastNamePaul Kim
                                                             Division of
Corporation Finance
Comapany NameFulgent Genetics, Inc.
                                                             Office of Life
Sciences
July 31, 2020 Page 2
cc:       Melanie Levy, Esq.
FirstName LastName